1. Academic Validation
  2. Identification and Benchmarking of Myokinasib-II as a Selective and Potent Chemical Probe for Exploring MLCK1 Inhibition

Identification and Benchmarking of Myokinasib-II as a Selective and Potent Chemical Probe for Exploring MLCK1 Inhibition

  • ACS Chem Biol. 2024 Oct 18;19(10):2165-2175. doi: 10.1021/acschembio.4c00336.
Gautam Kumar 1 Prema Kumari Agarwala 1 Aswin T Srivatsav 1 Ashok Ravula 2 G Ashmitha 2 Sreenath Balakrishnan 2 3 Shobhna Kapoor 1 Rishikesh Narayan 3 4
Affiliations

Affiliations

  • 1 Department of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai, Maharashtra 400076, India.
  • 2 School of Mechanical Sciences, Indian Institute of Technology Goa, Farmagudi, Ponda, Goa 403401, India.
  • 3 School of Interdisciplinary Life Sciences, Indian Institute of Technology Goa, Farmagudi, Ponda, Goa 403401, India.
  • 4 School of Chemical and Materials Sciences, Indian Institute of Technology Goa, Farmagudi, Ponda, Goa 403401, India.
Abstract

Deciphering the functional relevance of every protein is crucial to developing a better (patho)physiological understanding of human biology. The discovery and use of quality chemical probes propel exciting developments for developing drugs in therapeutic areas with unmet clinical needs. Myosin light-chain kinase (MLCK) serves as a possible therapeutic target in a plethora of diseases, including inflammatory diseases, Cancer, etc. Recent years have seen a substantial increase in interest in exploring MLCK biology. However, there is only one widely used MLCK modulator, namely, ML-7, that too with a narrow working concentration window and high toxicity profile leading to limited insights. Herein, we report the identification of a potent and highly selective chemical probe, Myokinasib-II, from the synthesis and structure-activity relationship studies of a focused indotropane-based compound collection. Notably, it is structurally distinct from ML-7 and hence meets the need for an alternative inhibitor to study MLCK biology as per the recommended best practices. Moreover, our extensive benchmarking studies demonstrate that Myokinasib-II displays better potency, better selectivity profile, and no nonspecific interference in relevant assays as compared to Other known MLCK inhibitors.

Figures
Products